In the current scenario, the emergence of drug resistance in Mycobacterium tuberculosis is the consequence of the failure of conventional diagnostics and treatment approach. To combats this global emergence of drug resistance, alternative approaches such as pathogen centric (use of repurposed drugs, novel analogs of existing anti-TB drugs and novel compounds a different mechanism of action), host-centric (immunomodulatory agents, therapeutic vaccines, immune and cellular therapies) and nano-based drugs/vaccines delivery approaches should be used in single or in combination. Diverse types of nano-carriers have gauged as auspicious diagnostics and drug delivery systems. In this focused review, we have suggested a long-term solution for combating the antimicrobial resistance and also an attractive means to increase patient's compliance and reduce treatment duration.